Shining the spotlight on shed KRAS in pancreatic cancer

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 361-363

  Sempere, Lorenzo F ^a   Korc, Murray ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Chronic pancreatitis; Kras; LigAmp assay; Pancreatic cancer; Pancreatic juice; PanIN; Screening test

Indexed keywords

COLLAGEN; K RAS PROTEIN;

ACINAR CELL; CARCINOGENESIS; CELL INFILTRATION; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FIBROBLAST; GENE MUTATION; INFLAMMATORY CELL; LOXP SITE; NOTE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION;

EID: 45349086607     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5582     Document Type: Note

References (26)

1. Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. Gastroenterol Clin North Am 2007; 36: 831-49, vi.
2. Friess H, Kleeff J, Buchler MW. Molecular pathophysiology of chronic pancreatitis - an update. J Gastrointest Surg 2003; 7: 943-5.
3. Witt H, Apte MV, Keim V, Wilson JS. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 2007; 132: 1557-73.
4. Rosty C, Geradts J, Sato N et al. p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 2003; 27: 1495-1501.
5. Adsay NV, Basturk O, Cheng JD, Andea AA. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol 2005; 15: 254-64.
6. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41: 2213-36.
7. Maitra A, Hruban RH. Pancreatic Cancer. Annu Rev Pathol 2007.
8. Talar-Wojnarowska R, Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 2006; 12: RA186-93.
9. Korc M. Biology of pancreatic cancer. In: Rutstgi AK, Crawford J (Eds.). Gastrointestinal Cancers. 2003: pp. 519-28.
10. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005; 7: 17-23.
11. Hruban RH, Adsay NV, bores-Saavedra J et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006; 66: 95-106.
12. Aguirre AJ, Bardeesy N, Sinha M et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-26.
13. Bardeesy N, Morgan J, Sinha M et al. Obligate roles for p16(Ink4a) and p19(Arf )-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol 2002; 22: 635-43.
14. Hingorani SR, Wang L, Multani AS et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-83.
15. Bardeesy N, Cheng KH, Berger JH et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006; 20: 3130-46.
16. Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 2007; 6: 2902-5.
17. Saha D, Datta PK, Beauchamp RD. Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 2001; 276: 29531-7.
18. Khalid A, Nodit L, Zahid M et al. Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses. Am J Gastroenterol 2006; 101: 2493-500.
19. Salek C, Benesova L, Zavoral M et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007; 13: 3714-20.
20. Maluf-Filho F, Kumar A, Gerhardt R et al. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol 2007; 41: 906-10.
21. Wu X, Lu XH, Xu T et al. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis 2006; 7: 170-4.
22. Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 2004; 28: 263-7.
23. Haug U, Hillebrand T, Bendzko P et al. Mutant-enriched PCR and allele-specific hybridization reaction to detect K-ras mutations in stool DNA: high prevalence in a large sample of older adults. Clin Chem 2007; 53: 787-90.
24. Shi C, Eshleman SH, Jones D et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004; 1: 141-7.
25. Shi C, Fukushima N, Abe T et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2007; 7.
26. Hsiang D, Friess H, Buchler MW, Ebert M, Butler J, Korc M. Absence of K-ras mutations in the pancreatic parenchyma of patients with chronic pancreatitis. Am J Surg 1997; 174: 242-6.